Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation Abvance is developing ABV100, a proprietary, clinically validated combination of insulin and glucagon with a goal of improving glycemic control while reducing hypoglycemia for people with diabetes who...